Biofrontera (BFRI) Restructuring Costs (2021)

Biofrontera's (BFRI) quarterly Restructuring Costs came in at $98000.0 in Q4 2021, down 50.75% quarter-over-quarter from $199000.0 in Q3 2021.

Biofrontera (BFRI) Restructuring Costs (2021) Analysis & Trends

Biofrontera's Restructuring Costs history runs 1 years deep, the most recent figure standing at $98000.0 for Q4 2021.

On a quarterly basis, Restructuring Costs changed N/A year-over-year to $98000.0 in Q4 2021; TTM through Dec 2021 was $764000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $752000.0, down 33.57% from the prior year.
Restructuring Costs retreated to $98000.0 in Q4 2021 per BFRI's latest filing, from $199000.0 in the prior quarter.
Across five years, Restructuring Costs topped out at $281000.0 in Q1 2021 and bottomed at $98000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Biofrontera	12.70 Mn	6.29 Mn	14.09 Mn

Download Data